Fluorouracil 2 % Topical Solution
RxNorm 310379
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 310379 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: fluorouracil 2 % Topical Solution.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Fluorouracil 20 mg/ML Topical Solution
(Atom ID: 12338702)
SYPrescribable
Synonym (SY):
5-5-fluorouracil 20 mg/ML Topical Solution
(Atom ID: 3850819)
SYPrescribable
Synonym (SY):
5-FU 20 mg/ML Topical Solution
(Atom ID: 3850818)
PSNPrescribable
Prescribable Name (PSN):
Fluorouracil 2 % Topical Solution
(Atom ID: 6394386)
SYPrescribable
Synonym (SY):
Fluorouracil 2 % Topical Solution
(Atom ID: 11836411)
PTPrescribable
Designated preferred name (PT):
Fluorouracil 20 mg/mL cutaneous solution
(Atom ID: 11436792)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely fluorouracil 20 mg/1 mL conventional release cutaneous solution (clinical drug)
(Atom ID: 11439930)
Patient Education
Fluorouracil Topical
Fluorouracil cream and topical solution are used to treat actinic or solar keratoses (scaly or crusted lesions [skin areas] caused by years of too much exposure to sunlight). Fluorouracil cream and topical solution are also used to treat a type of skin cancer called superficial basal cell carcinoma if usual types of treatment cannot be used. Fluorouracil is in a class of medications called antimetabolites. It works by killing fast-growing cells such as the abnormal cells in actinic keratoses and basal cell carcinoma.
[Learn More]
* Please review the disclaimer below.